DOCSLIB.ORG

Blefjell Sykehus HF Oslo Universitetssykehus HF

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Blefjell Sykehus HF Oslo Universitetssykehus HF Blefjell sykehus HF Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group O. Dahl;O. Fluge;E. Carlsen;J. N. Wiig;H. E. Myrvold;B. Vonen;N. Podhorny;O. Bjerkeset;T. J. Eide;T. B. Halvorsen;K. M. Tveit Acta Oncol 2009 PMID:19242829 Associations between ward atmosphere, patient satisfaction and outcome K. N. Jorgensen;V. Romma;T. Rundmo J Psychiatr Ment Health Nurs 2009 PMID:19281541 Variability in aggregometry response before and after initiation of clopidogrel therapy O. Meen;F. Brosstad;S. Bjornsen;T. M. Pedersen;G. Erikssen Scand J Clin Lab Invest 2009 PMID:19484660 [Can psychiatric acute teams reduce acute admissions to psychiatric wards?] O. B. Kolbjornsrud;F. Larsen;G. Elbert;T. Ruud Tidsskr Nor Laegeforen 2009 PMID:19823203 Oslo universitetssykehus HF A two-year prospective controlled study of bone mass and bone turnover in children with early juvenile idiopathic arthritis G. Lien;A. M. Selvaag;B. Flato;M. Haugen;O. Vinje;D. Sorskaar;K. Dale;T. Egeland;O. Forre Arthritis Rheum 2005 PMID:15751052 Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation B. Fellstrom;A. G. Jardine;I. Soveri;E. Cole;H. H. Neumayer;B. Maes;C. Gimpelewicz;H. Holdaas Am J Transplant 2005 PMID:15996249 Cytokines, bone turnover markers and weight change in candidates for lung transplantation L. Forli;O. J. Mellbye;J. Halse;O. Bjortuft;M. Vatn;J. Boe Pulm Pharmacol Ther 2008 PMID:17419084 The "Romsas in Motion" community intervention: mediating effects of psychosocial factors on forward transition in the stages of change in physical activity C. Lorentzen;Y. Ommundsen;A. K. Jenum;I. Holme Health Educ Behav 2009 PMID:18065570 Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study L. T. van Zyl;F. Lesperance;N. Frasure-Smith;A. I. Malinin;D. Atar;M. A. Laliberte;V. L. Serebruany J Thromb Thrombolysis 2009 PMID:18188512 Candesartan, NT-proBNP and recurrence of atrial fibrillation after electrical cardioversion A. Tveit;I. Seljeflot;I. Grundvold;M. Abdelnoor;H. Arnesen;P. Smith Int J Cardiol 2009 PMID:18201783 Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine- treated patients A. O. Vik-Mo;A. B. Birkenaes;J. Ferno;H. Jonsdottir;O. A. Andreassen;V. M. Steen Int J Neuropsychopharmacol 2008 PMID:18241359 Late regional density changes of the lung after radiotherapy for breast cancer R. Vagane;T. Danielsen;S. D. Fossa;E. Lokkevik;D. R. Olsen Radiother Oncol 2009 PMID:18262670 Involvement of the PRKCB1 gene in autistic disorder: significant genetic association and reduced neocortical gene expression C. Lintas;R. Sacco;K. Garbett;K. Mirnics;R. Militerni;C. Bravaccio;P. Curatolo;B. Manzi;C. Schneider;R. Melmed;M. Elia;T. Pascucci;S. Puglisi-Allegra;K. L. Reichelt;A. M. Persico Mol Psychiatry 2009 PMID:18317465 Instability in the latency of P3a/P3b brain potentials and cognitive function in aging A. M. Fjell;H. Rosquist;K. B. Walhovd Neurobiol Aging 2009 PMID:18339453 Berberine decreases PCSK9 expression in HepG2 cells J. Cameron;T. Ranheim;M. A. Kulseth;T. P. Leren;K. E. Berge Atherosclerosis 2008 PMID:18355829 A randomized trial comparing monopolar electrodes using glycine 1.5% with two different types of bipolar electrodes (TCRis, Versapoint) using saline, in hysteroscopic surgery A. Berg;L. Sandvik;A. Langebrekke;O. Istre Fertil Steril 2009 PMID:18371962 EULAR points to consider for conducting clinical trials in systemic lupus erythematosus C. Gordon;G. Bertsias;J. P. Ioannidis;J. Boletis;S. Bombardieri;R. Cervera;C. Dostal;J. Font;I. M. Gilboe;F. Houssiau;T. W. Huizinga;D. Isenberg;C. G. Kallenberg;M. A. Khamashta;J. C. Piette;M. Schneider;J. S. Smolen;G. Sturfelt;A. Tincani;R. Van Vollenhoven;D. T. Boumpas Ann Rheum Dis 2009 PMID:18388158 Cardiovascular risk-factors predict progression of urinary albumin-excretion in a general, non-diabetic population: a gender-specific follow-up study M. D. Solbu;J. Kronborg;B. O. Eriksen;T. G. Jenssen;I. Toft Atherosclerosis 2008 PMID:18405901 Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers D. G. Evans;K. N. Gaarenstroom;D. Stirling;A. Shenton;L. Maehle;A. Dorum;M. Steel;F. Lalloo;J. Apold;M. E. Porteous;H. F. Vasen;C. J. van Asperen;P. Moller J Med Genet 2009 PMID:18413372 EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints G. K. Bertsias;J. P. Ioannidis;J. Boletis;S. Bombardieri;R. Cervera;C. Dostal;J. Font;I. M. Gilboe;F. Houssiau;T. Huizinga;D. Isenberg;C. G. Kallenberg;M. Khamashta;J. C. Piette;M. Schneider;J. Smolen;G. Sturfelt;A. Tincani;R. van Vollenhoven;D. T. Boumpas;C. Gordon Ann Rheum Dis 2009 PMID:18434449 Therapeutic hypothermia after out-of hospital cardiac arrest: how to secure worldwide implementation E. Soreide;K. Sunde Curr Opin Anaesthesiol 2008 PMID:18443491 Peripheral neuropathy and severe malnutrition following duodenal switch E. T. Aasheim;D. Hofso;J. Hjelmesaeth;R. Sandbu Obes Surg 2008 PMID:18463930 Hirudin versus heparin for use in whole blood in vitro biocompatibility models F. Bexborn;A. E. Engberg;K. Sandholm;T. E. Mollnes;J. Hong;K. Nilsson Ekdahl J Biomed Mater Res A 2009 PMID:18470919 Vitamin C consumption is associated with less progression in carotid intima media thickness in elderly men: A 3-year intervention study I. Ellingsen;I. Seljeflot;H. Arnesen;S. Tonstad Nutr Metab Cardiovasc Dis 2009 PMID:18472409 Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment E. Brodin;I. Seljeflot;H. Arnesen;M. Hurlen;H. Appelbom;J. B. Hansen Thromb Res 2009 PMID:18474393 Acetabular dysplasia as an aetiological factor in development of hip osteoarthritis K. Johnsen;R. Goll;O. Reikeras Int Orthop 2009 PMID:18478228 Morphological evidence for vesicular glutamate release from astrocytes L. H. Bergersen;V. Gundersen Neuroscience 2009 PMID:18479831 Smoking and the risk of breast cancer in BRCA1 and BRCA2 carriers: an update O. Ginsburg;P. Ghadirian;J. Lubinski;C. Cybulski;H. Lynch;S. Neuhausen;C. Kim-Sing;M. Robson;S. Domchek;C. Isaacs;J. Klijn;S. Armel;W. D. Foulkes;N. Tung;P. Moller;P. Sun;S. A. Narod Breast Cancer Res Treat 2009 PMID:18483851 Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran G. Agnelli;B. I. Eriksson;A. T. Cohen;D. Bergqvist;O. E. Dahl;M. R. Lassen;P. Mouret;N. Rosencher;M. Andersson;A. Bylock;E. Jensen;B. Boberg Thromb Res 2009 PMID:18485453 Error-related negativity is mediated by fractional anisotropy in the posterior cingulate gyrus-- a study combining diffusion tensor imaging and electrophysiology in healthy adults L. T. Westlye;K. B. Walhovd;A. Bjornerud;P. Due-Tonnessen;A. M. Fjell Cereb Cortex 2009 PMID:18502729 Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy P. M. Okin;E. Gerdts;S. E. Kjeldsen;S. Julius;J. M. Edelman;B. Dahlof;R. B. Devereux Hypertension 2008 PMID:18504323 Interaction between renal function and microalbuminuria for cardiovascular risk in hypertension: the nordic diltiazem study P. Farbom;B. Wahlstrand;P. Almgren;S. Skrtic;J. Lanke;L. Weiss;S. Kjeldsen;T. Hedner;O. Melander Hypertension 2008 PMID:18504324 Functional outcome after lumbar closing wedge osteotomy in ankylosing spondylitis J. I. Brox;A. Helle;R. Sorensen;R. Gunderson;R. Riise;O. Reikeras Int Orthop 2009 PMID:18506442 Performance-based functional evaluation of non-operative and operative treatment after anterior cruciate ligament injury H. Moksnes;M. A. Risberg Scand J Med Sci Sports 2009 PMID:18510592 The phenomenology of recurrent brief depression with and without hypomanic features H. Lovdahl;S. Andersson;T. Hynnekleiv;U. F. Malt J Affect Disord 2009 PMID:18538858 A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small- cell lung cancer B. H. Gronberg;R. M. Bremnes;U. Aasebo;P. Brunsvig;O. Flotten;T. Amundsen;C. von Plessen;M. Wang;S. Sundstrom Lung Cancer 2009 PMID:18538889 Living as a drug addict in Oslo, Norway--a study focusing on nutrition and health M. Saeland;M. Haugen;F. L. Eriksen;A. Smehaugen;M. Wandel;T. Bohmer;A. Oshaug Public Health Nutr 2009 PMID:18549520 Rapid and severe rise in static and pulsatile intracranial pressures during a generalized epileptic seizure O. Solheim;A. Vik;S. Gulati;P. K. Eide Seizure 2008 PMID:18554932 Change in the use of hormone replacement therapy and the incidence of fracture in Oslo H. E. Meyer;C. M. Lofthus;A. J. Sogaard;J. A. Falch Osteoporos Int 2009 PMID:18563511 Establishing laparoscopic Roux-en-Y gastric bypass: perioperative outcome and characteristics of the learning curve T. T. Sovik;E. T. Aasheim;J. Kristinsson;C. F. Schou;L. M. Diep;A. Nesbakken;T. Mala Obes Surg 2009 PMID:18566869 Health-related quality of life during the last three months of life in patients with advanced cancer M. A. Elmqvist;M. S. Jordhoy;K. Bjordal;S. Kaasa;M. Jannert Support Care Cancer 2009 PMID:18581147 Expression of genes involved in excitatory neurotransmission in anoxic crucian carp (Carassius carassius) brain S. Ellefsen;G. K. Sandvik;H. K. Larsen;K. O. Stenslokken;D. A. Hov;T. A. Kristensen;G. E. Nilsson Physiol Genomics 2008 PMID:18593861 Intravenous administration of CP-4055 (ELACYT) in patients with solid tumours. A Phase I study S. Dueland;S. Aamdal;M. J. Lind;H. Thomas;M. L. Sandvold;J. M. Gaullier;W. Rasch Acta Oncol 2009 PMID:18607882 Mortality and causes of death after hospital-treated self-poisoning in Oslo: a 20-year follow- up M.
Load more

Recommended publications
  • Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal
    testinal & in D o i tr g s e Journal of Gastrointestinal & a s t G i v f e o Narayanan et al., J Gastrointest Dig Syst 2018, 8:1 S l y a s n r ISSN: 2161-069Xt Digestive System DOI: 10.4172/2161-069X.1000553 e u m o J Research Article Open Access Real World Efficacy and Tolerability of Acotiamide, in Relieving Meal- related Symptoms of Functional Dyspepsia Varsha Narayanan*, Amit Bhargava and Shailesh Pallewar 1Department of Medical Services and Research, Lupin Ltd., India *Corresponding author: Narayanan V, Department of Medical Services and Research, Lupin Ltd., Mumbai, India, Tel: +912266402222; E-mail: [email protected] Received date: February 09, 2018; Accepted date: February 21, 2018; Published date: February 27, 2018 Copyright: © 2018 Narayanan V, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Background: Functional Dyspepsia (FD) is a highly prevalent clinical condition that imposes negative economic burden on health-care system as well as greatly impairs quality of life. Treatment of non-specific and bothersome meal-related FD symptoms like post-prandial fullness, upper abdominal bloating and early satiety, is a therapeutic challenge for the clinicians as poorly-defined and ill-understood pathogenesis has hampered efforts to develop effective treatments. Acotiamide is first-in-class drug that exerts its gastro-kinetic effect by enhancing acetylcholine release. Though evidence of its efficacy and tolerance are available through randomized clinical trials, real world data from its regular in-clinic use is lacking.
    [Show full text]
  • PN0496-Acotiamide.Pdf
    Acotiamide hydrochloride hydrate (Acofide®) 盐酸阿考替胺 Z-338 in Zeria; YM-443 in Astellas Tablet, oral, EQ 100 mg acotiamide Acotiamide is a peripheral acetylcholinesterase inhibitor, indicated for the treatment of functional dyspepsia (FD), which was first-in-class drug to treat FD in the world and approved in 2013 by Japan PMDA. It was originally discovered by Zeria, and co-developed with Astellas. The drug is co-marketing in Japan with a single brand name. The human recommended starting dose is 100 mg at a time, and 3 times a day before meals. Worldwide Key Approvals Global Sales ($Million) Key Substance Patent Expiration 2016-May (US5981557A) 2016-May (EP0870765B1) 2013-Mar (JP) Not available 2021-May (JP3181919B2) 2016-May (CN1063442C) Mechanism of Action Acotiamide hydrochloride hydrate is an acetylcholinesterase (AChE) inhibitor and enhanced the acetylcholine (ACh)-induced contraction and motility of the gastric antrum and the gastric body. Target Binding Selectivity In vitro Efficacy In vivo Efficacy Mixed pattern: Ki1= 0.61 µM Effect dose of contraction in gastric sample: Significantly improved the gastrointestinal motility: Ki2= 2.7 µM ACh-induced: at 1 µM In normal and gastric hypomotility dogs: at 10 mg/kg. Inhibition: IC50= 3 µM Electrical-induced: at 0.3 µM In gastric hypomotility rats: at 100 mg/kg. Pharmacokinetics Parameters Rats Dogs Healthy Humans 3 10 3 10 50 mg 100 mg 200 mg 400 mg 800 mg Dose (mg/kg) (i.v.) (p.o.) (i.v.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) (p.o.) Tmax (hr) - 0.08 - 0.5 2.75 2.42 2.08 2.25 2.13 Cmax
    [Show full text]
  • TELEMARK BOTANISKE FORENING LISTÉRA - Tidsskrift for Telemark Botaniske Forening (NBF, Telemarksavdelingen) 20
    2 - 2 0 0 5 TELEMARK BOTANISKE FORENING LISTÉRA - Tidsskrift for Telemark Botaniske Forening (NBF, Telemarksavdelingen) 20. årgang, 2005, nummer 2 **************************************************************** ADRESSER OG TELEFONER: TELEMARK BOTANISKE FORENING, Postboks 25 Stridsklev, 3904 Porsgrunn Postgirokonto: 0530 3890647. Foreningens e-mail-kontakt: [email protected] Foreningens hjemmeside: www.miclis.no/tbf Kasserer: Åse Halvorsen, Langerødvegen 4, 3719 Skien Tlf.: 35 50 01 35 Styremedlem: Esther Broch, Oscars gate 53, 3725 Skien Tlf.: 35 53 05 86 Styremedlem: Målfrid Ergon, Steinringen 47, 3931 Porsgrunn Tlf.: 35 51 25 16 Styremedlem: Bjørn Erik Halvorsen, Utsikten 4, 3911 Porsgrunn Tlf.: 35 55 42 57 Styremedlem: Trond Risdal, Orionvegen 88, 3942 Porsgrunn Tlf.: 35 51 29 69 1. Varamedlem: Grete Stendalen, Wettergreensveg 5, 3738 Skien Tlf.: 35 59 43 73 2. Varamedlem: Anne Vinorum, Raskenlundvegen 29, 3928 Porsgrunn Tlf: 35 51 25 16 Floraatlas: Bjørn Erik Halvorsen, Utsikten 4, 3911 Porsgrunn Tlf.: 35 55 42 57 Roger Halvorsen, Hanevoldvn. 15, 3090 Hof Mobiltelefon: 41 50 54 12 Trond Risdal, Orionvegen 88, 3942 Porsgrunn Tlf.: 35 51 29 69 **************************************************************** I redaksjonen: Norman Hagen (e-post: [email protected]), Priscilla Hansen (e-post: peahans@online. no), Grete Stendalen (e-post: [email protected]) Forsidebildet: Bukkeblad (”Saltgras”). Akvarell av Sigrid Nordskog. Se art. på side 105. ISSN: 0801 - 9460 Listéra 2005, nr. 2 3 FRA REDAKSJONEN Tidlig i april 1980 kunne Sønder-Jylland, Skåne (to ganger), telemarkinger lese i lokalavisene Väster-Götland, Møn, Valdres, innbydelsen til et møte for botanisk Langeland i Danmark, Røros og interesserte. Det skulle holdes på Karmøy. Opplevelser sto i kø – er det Skomvær kafé i Porsgrunn 17.
    [Show full text]
  • Ringvirkninger Av Reiseliv I Buskerud, Telemark Og Vestfold
    Ringvirkninger av reiseliv i Buskerud, Telemark og Vestfold Petter Dybedal TØI rapport 780/2005 TØI rapport 780/2005 Ringvirkninger av reiseliv i Buskerud, Telemark og Vestfold Petter Dybedal Transportøkonomisk institutt (TØI) har opphavsrett til hele rapporten og dens enkelte deler. Innholdet kan brukes som underlagsmateriale. Når rapporten siteres eller omtales, skal TØI oppgis som kilde med navn og rapport- nummer. Rapporten kan ikke endres. Ved eventuell annen bruk må forhåndssamtykke fra TØI innhentes. For øvrig gjelder åndsverklovens bestemmelser. ISSN 0802-0175 ISBN 82-480-0520-8 Papirversjon ISBN 82-480-052-6 Elektronisk versjon Oslo, juni 2005 Tittel: Ringvirkninger av reiseliv i Buskerud, Title: Economic impact of tourism in the Buskerud, Telemark og Vestfold Telemark and Vestfold counties of Norway Forfatter(e): Petter Dybedal Author(s): Petter Dybedal TØI rapport 780/2005 TØI report 780/2005 Oslo, 2005-06 Oslo: 2005-06 48 sider 48 pages ISBN 82-480-0520-8 Papirversjon ISBN 82-480-0520-8 Paper version ISBN 82-480-0521-6 Elektronisk versjon ISBN 82-480-0521-6 Electronic version ISSN 0802-0175 ISSN 0802-0175 Finansieringskilde: Financed by: Buskerud, Vestfold og Telemark fylkeskommuner - The county administrations of Buskerud, Telemark and BTV, Innovasjon Norge Buskerud og Vestfold og Vestfold, Innovasjon Norge Buskerud and Vestfold, and Innovasjon Norge Telemark Innovasjon Norge Telemark Prosjekt: 3074 Fylkesvis ringvirkningsanalyse for Project: 3074 County level impact of tourism in the reiseliv i BTV-regionen BTV-region Prosjektleder:
    [Show full text]
  • Bremnes Seashore Joins Salmon Group
    Press release 2020-10-26 Bremnes Seashore joins Salmon Group SALMA producer Bremnes Seashore today enters as shareholder in Salmon Group, a network of 41 fish farmers who emphasize local ownership and interaction with the local communities. Through the ownership, Bremnes Seashore also takes part in Salmon Group's innovative feed collaboration. - Salmon Group is very pleased to welcome a company who has such a good eye for the important drivers. Through a long period of conversations and discussion on important matters for us both, we are now well acquainted to each other. We are very confident that Bremnes Seashore is an aquaculture farmer who will fit well in our network, says Jan Olav Langeland, CEO of Salmon Group. - We have a common set of values with the other owners in Salmon Group, a group of salmon and trout farmers who are at the forefront of the development of sustainable farming. All companies will contribute to activity and jobs in the local communities along the coast. This makes us a good fit with the network, says Einar Eide, CEO of Bremnes Seashore. Common sustainability philosophy In recent years, Salmon Group has distinguished itself with its systematic and concrete work on sustainability. Based on their feasibility study "Sustainable farming of salmon and trout - What is that?", the network has been able to make specific adjustments of its own feed recipe. The changes are specific and have so far resulted in a 36% reduction in the carbon footprint from the production of salmon and trout that are fed with SG feed. - Salmon Group has taken major steps to reduce the footprint from feed production and transport and set the standard for sustainable feed for the aquaculture industry.
    [Show full text]
  • Pharmacological Agents Currently in Clinical Trials for Disorders in Neurogastroenterology
    Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri J Clin Invest. 2013;123(10):4111-4120. https://doi.org/10.1172/JCI70837. Clinical Review Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in understanding the mechanisms of these disorders, through basic and translational research, and in targeting the receptors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastroparesis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain. Find the latest version: https://jci.me/70837/pdf Review Pharmacological agents currently in clinical trials for disorders in neurogastroenterology Michael Camilleri Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, Minnesota, USA. Esophageal, gastrointestinal, and colonic diseases resulting from disorders of the motor and sensory functions represent almost half the patients presenting to gastroenterologists. There have been significant advances in under- standing the mechanisms of these disorders, through basic and translational research, and in targeting the recep- tors or mediators involved, through clinical trials involving biomarkers and patient responses. These advances have led to relief of patients’ symptoms and improved quality of life, although there are still significant unmet needs. This article reviews the pipeline of medications in development for esophageal sensorimotor disorders, gastropa- resis, chronic diarrhea, chronic constipation (including opioid-induced constipation), and visceral pain.
    [Show full text]
  • Årsskrift for Modum Historielag 2006 21
    ÅRSSKRIFT FOR MODUM HISTORIELAG 2006 21. ÅRGANG ÅRSSKRIFT FOR MODUM HISTORIELAG 2006 21. ÅRGANG I redaksjonen: Jon Mamen Erling Diesen Aase Hanna Fure Asbjørn Lind Andreas Øvergaard Historielagets styre: Wermund Skyllingstad, leder/sekretær Per A. Knudsen, nestleder Aase Hanna Fure, kasserer Ingar Hellerud Ragnhild Flannum Liv Enger Sigmund Heier Bjørg Randi Hovde Erling Løken Historielagets adresse: Postboks 236, 3371 Vikersund Gamle Modums adresse: Jon Mamen Fjerdingstadveien, 3330 Skotselv e-post: [email protected] Tlf. 32 75 30 65 Layout og trykk: Caspersens Trykkeri AS, Vikersund Innholdsfortegnelse: JON MAMEN: RUNE MARTINSEN: Mathias Amlund ............................................... 3 40 år siden det første Ørpen-stevnet .............. 42 ARNE SØRENSEN: AASE HANNA FURE: Presten og klokkeren ........................................ 10 Overgang til ny skole høsten 1951 ................ 45 INGAR HELLERUD: HANS P. FURE: Sundsted og oversett i Tale for dagen 17. mai 1945 ............................ 47 Vestre Sponefjerdingen m. m. ........................ 11 THORBJØRN FORMO: TORE BRØNNER: Risper fra Modum II ........................................ 49 Kalkovnene rundt Mælum-Damtjern ........... 16 INGER-LISE MOEN: ARNT BERGET: Hilmar Moens erindringer ............................. 50 Skjebnesvangert griseslakt............................... 22 BJØRG RANDI HOVDE: OLAV SØRENSEN: Et dykk i gamle papirer .................................. 57 Vikersund meieri 1935 ..................................... 26 ØYVIND HAUGEN: ANDREAS ØVERGAARD: Ernst
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • International Response to Infectious Salmon Anemia: Prevention, Control, and Eradication: Proceedings of a Symposium; 3Ð4 September 2002; New Orleans, LA
    United States Department of Agriculture International Response Animal and Plant Health to Infectious Salmon Inspection Service Anemia: Prevention, United States Department of the Interior Control, and Eradication U.S. Geological Survey United States Department of Commerce National Marine Fisheries Service Technical Bulletin No. 1902 The U.S. Departments of Agriculture (USDA), the Interior (USDI), and Commerce prohibit discrimination in all their programs and activities on the basis of race, color, national origin, sex, religion, age, disability, political beliefs, sexual orientation, or marital or family status. (Not all prohibited bases apply to all programs.) Persons with disabilities who require alternative means for communication of program information (Braille, large print, audiotape, etc.) should contact USDA’s TARGET Center at (202) 720–2600 (voice and TDD). To file a complaint of discrimination, write USDA, Director, Office of Civil Rights, Room 326–W, Whitten Building, 1400 Independence Avenue, SW, Washington, DC 20250–9410 or call (202) 720–5964 (voice and TDD). USDA, USDI, and Commerce are equal opportunity providers and employers. The opinions expressed by individuals in this report do not necessarily represent the policies of USDA, USDI, or Commerce. Mention of companies or commercial products does not imply recommendation or endorsement by USDA, USDI, or Commerce over others not mentioned. The Federal Government neither guarantees nor warrants the standard of any product mentioned. Product names are mentioned solely to report factually on available data and to provide specific information. Photo credits: The background illustration on the front cover was supplied as a photo micrograph by Michael Opitz, of the University of Maine, and is reproduced by permission.
    [Show full text]
  • Monitoring Anthropogenic Activity in the Hardangervidda Wild Reindeer Range Possible Applications of Crowdsourced Strava-Data in Remote Settings
    Faculty of Biosciences, Fisheries and Economics. Department of Arctic and Marine Biology. Monitoring anthropogenic activity in the Hardangervidda wild reindeer range Possible applications of crowdsourced Strava-data in remote settings Vilde Grøthe Holtmoen Master’s thesis in Biology, BIO-3950, May 2021 Preface This master thesis (60ECTS) was written as the final thesis of the study-program Masters in Biology at University of Tromsø (UiT), faculty of Biosciences, Fisheries and Economics, department of Arctic and Marine Biology. My supervisors has been Audun Stien (UiT) and Vegard Gundersen (NINA, dep. Lillehammer). Maps showing habitat suitability for wild reindeer on Hardangervidda in summer used in this thesis, was created by Manuela Panzacchi and Bram Van Moorter for NINA’s project Renewable Reindeer (RenewableReindeer (nina.no)) and will be published in an upcoming report (Tema-rapport) for NINA in 2021 (Panzacchi et.al., 2021, in press). Methods, analyses and results are previously published in Panzacchi et.al., 2015a. NINA had the main idea for this thesis and has contributed with the material for my analyses such as raw data from automatic counters, Strava-data and GPS-data from GPS-collared wild reindeer. 2 Abstract Seen in light of the increasing interest of nature-based tourism and recreational outdoor activities in Norway the last decades (Reimers, Eftestøl & Colman, 2003; Haukeland, Grue & Veisten, 2010), spatiotemporal information on human activity in remote areas and knowledge about how this activity may affect wildlife and nature is a crucial part of a knowledge-based management (Gundersen et.al., 2011, p.14; Gundersen, Strand & Punsvik, 2016, p.166). Hardangervidda is the largest national park in mainland Norway and is also home to the largest population of wild mountain reindeer (Rangifer tarandus tarandus), a specie of international responsibility in management and conservation and recently added to the Norwegian red list (Kjørstad et.al., 2017, p.26; Artsdatabanken, 2021).
    [Show full text]
  • Country Site Town Company Number of Projectors Technology
    Country Site Town Company Number of Technology Projector Projector's type Projector's Server Number of Supplier of 3D projectors resolution 3D screens technology N Tysvær kommunales kino Aksdal TYSVÆR KOMMUNALES 2 DLP Cinema Christie CP2220/ CP2230 2K Doremi 1 Dolby KINO N Aurora Kino Alta Alta AURORA KINO 1 DLP Cinema Christie CP2000ZX 2K Doremi 1 XpanD N Arendal Kino Arendal ARENDAL KINO 4 DLP Cinema Christie CP2210/ CP2220/ CP2230 2K Doremi 2 RealD N Asker Kino Asker NORSK KINO 5 DLP Cinema/ Barco/Sony DP2000/ DP3000/SRX-R320 2K/4K Dolby/Sony 5 RealD SXRD N Askim Kino Askim NORSK KINO 2 SXRD Sony SRX-R320 4K Sony 2 RealD N Trudvang Kino Aurland TRUDVANG KINO 1 DLP Cinema Christie CP2220 2K Doremi 1 Dolby N Friberg Kino Balestrand FRIBERG KINO 1 DLP Cinema Christie CP2210 2K Doremi - - N KonsertPaleet Bergen BERGEN KINO 13 DLP Cinema/ Christie/Sony CP2210/ CP2220/ CP2230/SRX- 2K/4K Doremi/Sony 3 RealD SXRD R220/SRX-R320 N Magnus Barfot Bergen BERGEN KINO 5 DLP Cinema Christie/ Barco CP2230/ DP2000/ DP3000 2K Doremi 3 RealD N Fram Kino Bodø FRAM KINO 3 DLP Cinema Christie CP2220/ CP2230 2K Doremi 1 Dolby N Bømlo kino Bremnes BØMLO KINO 3 DLP Cinema Christie CP2220/ CP2230 2K Doremi 1 Dolby N Storstova Bryne STORSTOVA PÅ JÆREN 1 DLP Cinema Christie CP2230 2K Doremi 1 Dolby N Fjaler Kino Dale I Sunnfjord FJALER KINO 1 DLP Cinema Christie CP2220 2K Doremi 1 Dolby N Sentrum Kino Dokka SENTRUM KINO 1 DLP Cinema Christie CP2230 2K Doremi - - N Kinocity Drammen KINOCITY 6 DLP Cinema Christie CP2220/ CP2230 2K Doremi 2 MasterImage N Egersund
    [Show full text]
  • Gulen Kyrkjelydsblad Nr. 1, 2019.Pdf
    Gulen kyrkjelydsblad Nr 1 April 2019 62. årgang Vikarprest Børge Ryland og flinke konfirmantar gjennomførte ei flott samtalegudsteneste i Gulen kyrkje 17.03.19. (Foto: Ivar Rutledal) REDAKSJON: Anne R. Tveit, tlf. Redaksjonen 48228353. Eivindvikvegen 1117, 5966 Eivindvik [email protected] Kyrkjelydsbladet kjem i år med fire nummer: Nr.1 (påske/konfirmasjon), KORREKTUR: Marit Sandal, 5966 nr.2 (juni), nr.3 (haust, i samband med Eivindvik Tlf. 57784129 / 95997182 soknerådsvalet), og 4 (desember/jul). BANKGIROKONTO: 3817 15 51282 GOD PÅSKE til lesarane våre! Kontingenten er fri. Innsendingsfrist neste nr: 20. mai. TRYKKERI: Norengros, 3701 Skien SOKNEPREST i GULEN, BREKKE OG MJØMNA SOKN: Jens Linde, 5966 Eivindvik. Tlf. 97509035 [email protected] KYRKJEVERJE: Trude Brosvik, 5966 Eivindvik, Tlf. 57782090/91314389 [email protected] Kontor:Ikkje onsd. KONTORPERSONALE: Margrethe Skåden, Tlf. 57782093 Kontortid torsdag kl.12.40-16.00 og fredag kl.08.00-12.00. ORGANIST: Peter Tiborc Jobbagy, 5966 Eivindvik. Tlf. kontor 57782092. SOKNERÅD/FELLESRÅD: Gulen sokn: Maike Norman Bøe. Tlf. 95349801. [email protected] Brekke sokn: Cathrine Waage Tveit. Tlf. 91759076. [email protected] Mjømna sokn: Bente Haugen. Tlf. 99264861. [email protected] Fellesråd: Målfrid Undertun. Tlf. Altarteppet på Dalsøyra 41610983. [email protected] Teppet er laga ca. år 1995-97, av ungdomstrinnet på Dalsøyra skule. KYRKJA SI HEIMESIDE: www.gulen.kyrkja.no Alle elevane laga kvar si rute. Nina Dyregrov laga midtruta. FACEBOOK: Er du på Facebook, kan Agnes Grahl Madsen sydde rutene du gå inn på gruppa «Kyrkja i Gulen» og saman. Teppet har sidan vore brukt på «like» sida vår.
    [Show full text]